# Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma

Source: https://onco.cc/trials/nct01497275/  
OnCo record `nct01497275` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Rituximab, Bortezomib and Ibritumomab tiuxetan in Mantle cell lymphoma, run by Duke University, recorded as terminated on the registry.

## Summary

Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT01497275 by Duke University, with 5 participants recorded, started 2012-02 and due to reach its primary completion in 2014-05. Interventions recorded: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan. Conditions recorded: Mantle-Cell Lymphoma.

Linked to the drug Ibritumomab tiuxetan because the registry names it among its interventions and Mantle cell lymphoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01497275
- Phase: 2
- Setting: A Phase II Study Evaluating Combined Zevalin(Ibritumomab Tiuxetan)and Velcade(Bortezomib)in Relapsed/Refractory Mantle Cell Lymphoma
- Sponsor: Duke University
- Enrolled: 5

## Sources

- ClinicalTrials.gov NCT01497275: https://clinicaltrials.gov/study/NCT01497275

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [Bortezomib](https://onco.cc/drugs/bortezomib/), [Ibritumomab tiuxetan](https://onco.cc/drugs/ibritumomab-tiuxetan/), [Rituximab](https://onco.cc/drugs/rituximab/)

---
JSON: https://onco.cc/api/v1/entities/nct01497275.json